Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.

MLA

Dellanna, F., et al. “Dosing Strategies for Conversion of Haemodialysis Patients from Short-Acting Erythropoiesis Stimulating Agents to Once-Monthly C.E.R.A.: Experience from the MIRACEL Study.” International Journal of Clinical Practice, vol. 65, no. 1, Jan. 2011, pp. 64–72. EBSCOhost, https://doi.org/10.1111/j.1742-1241.2010.02551.x.

APA

Dellanna, F., Winkler, R. E., Bozkurt, F., Schettler, V., Graf, S., Bockreiss, N., & Fliser, D. (2011). Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. International Journal of Clinical Practice, 65(1), 64–72. https://doi.org/10.1111/j.1742-1241.2010.02551.x

Chicago

Dellanna, F, R E Winkler, F Bozkurt, V Schettler, S Graf, N Bockreiss, and D Fliser. 2011. “Dosing Strategies for Conversion of Haemodialysis Patients from Short-Acting Erythropoiesis Stimulating Agents to Once-Monthly C.E.R.A.: Experience from the MIRACEL Study.” International Journal of Clinical Practice 65 (1): 64–72. doi:10.1111/j.1742-1241.2010.02551.x.